Drug Trial Radar · NCT03232632
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
Last checked: Nov 20, 2026Latest source record: Aug 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
Mar 15, 2017
Primary completion
Sep 15, 2019
Study completion Sep 15, 2019
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2017
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.
Conditions
- Cardiac Amyloidosis
Interventions
PET with 18 F-FlutemetamolDrug
PET with 18 F-Flutemetamol (Vizamyl ®)
Primary outcomes
What the sponsor says the trial is designed to measure.
- ratio Heart/ Upper MediastinumTime frame: average of last 15 minutes
- standardized uptake value (SUV) measuresTime frame: average of last 15 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Toulouse
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.